title: [Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
authors.forename: T
authors.initials: T
authors.lastname: Banaschewski
authors.forename: M
authors.initials: M
authors.lastname: Döpfner
authors.forename: A
authors.initials: A
authors.lastname: Rothenberger
authors.forename: H -C
authors.initials: H-
authors.lastname: Steinhausen
mesh_terms: D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003692:Delayed-Action Preparations; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects; D011613:Psychotherapy; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride